Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice
Article first published online: 10 APR 2012
© 2011 Genentech Inc. British Journal of Pharmacology © 2011 The British Pharmacological Society
British Journal of Pharmacology
Special Issue: Themed Section: Secretin Family (Class B) G Protein-Coupled Receptors - from Molecular to Clinical Perspectives. Guest Editors: David R Poyner and Debbie L Hay
Volume 166, Issue 1, pages 368–377, May 2012
How to Cite
Bumbaca, D., Xiang, H., Boswell, C. A., Port, R. E., Stainton, S. L., Mundo, E. E., Ulufatu, S., Bagri, A., Theil, F.-P., Fielder, P. J., Khawli, L. A. and Shen, B.-Q. (2012), Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. British Journal of Pharmacology, 166: 368–377. doi: 10.1111/j.1476-5381.2011.01777.x
- Issue published online: 10 APR 2012
- Article first published online: 10 APR 2012
- Accepted manuscript online: 10 NOV 2011 08:30AM EST
- Received; 10 August 2011; Revised; 6 October 2011; Accepted; 21 October 2011
Figure S1 Tissue distribution at 24 h post dose following i.v. administration of [111In]-DOTA-MNRP1685A or [111In]-DOTA-control IgG1 at 7.4 MBq·kg−1 (0.05 mg·kg−1) (n = 4). The radioactivity is represented as percentage of injected dose per gram of tissue (%ID·g−1).
|BPH_1777_sm_FigS1.tif||166K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.